title: Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib
creator: Ganten, Maria-Katharina
creator: Schuessler, Max
creator: Bruckner, Thomas
creator: Ganten, Tom M.
creator: Koschny, Ronald
subject: ddc-610
subject: 610 Medical sciences Medicine
description: Objective: To date, sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC). Pancreatic atrophy has recently been reported in 2 patients as a novel side effect after long-term sorafenib treatment.     Methods: We retrospectively analyzed clinical and radiological data of patients with advanced HCC with long-term treatment of sorafenib (median 279 days, range 153–826 days). Pancreata were semi-manually segmented section by section to calculate the pancreas volumes before and under sorafenib treatment.     Results: Sorafenib reduced pancreatic volume in 18/19 (95%) HCC patients with a mean pancreatic volume loss of 25% (p = 0.002). Pancreatic volume loss depended on the dose (r = 0.36) and exposure time of sorafenib (r = 0.35) and was detectable as early as after 3 months of sorafenib treatment and already after a cumulative sorafenib dose of <100 g. Median overall survival was 13.2 months (range 7.8–31.3 months) but did not correlate with sorafenibinduced pancreatic volume reduction (hazard ratio 1.002, 95% confidence interval 0.981–1.060, p = 0.24).     Conclusion: We could confirm pancreatic atrophy as a novel adverse event of sorafenib therapy in HCC patients, correlating with sorafenib dose and exposure time.
publisher: Karger
date: 2015
type: Article
type: info:eu-repo/semantics/article
type: NonPeerReviewed
format: application/pdf
identifier: https://archiv.ub.uni-heidelberg.de/volltextserverhttps://archiv.ub.uni-heidelberg.de/volltextserver/27248/1/377681.pdf
identifier: DOI:10.11588/heidok.00027248
identifier: https://doi.org/10.1159/000377681
identifier: urn:nbn:de:bsz:16-heidok-272489
identifier:   Ganten, Maria-Katharina ; Schuessler, Max ; Bruckner, Thomas ; Ganten, Tom M. ; Koschny, Ronald  (2015) Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib.  Oncology, 89 (2).  pp. 88-94.  ISSN 0030-2414 (Druck-Ausg.), 1423-0232 (Online-Ausg.)     
relation: https://archiv.ub.uni-heidelberg.de/volltextserver/27248/
rights: info:eu-repo/semantics/openAccess
rights: http://archiv.ub.uni-heidelberg.de/volltextserver/help/license_urhg.html
language: eng